On the other hand, we studied the correlation of L1CAM+ EVs levels in L1CAM-captured spots and GLAST+ EVs levels in GLAST-captured spots from all groups with the NfL (axonal damage) [19,20] and GFAP (MS progression) established biomarkers [21]. This evidence concerns the gene L1CAM and myeloid sarcoma.